...
首页> 外文期刊>Clinical and Translational Allergy >Increasing incidence of anaphylaxis in Hong Kong from 2009 to 2019—discrepancies of anaphylaxis care between adult and paediatric patients
【24h】

Increasing incidence of anaphylaxis in Hong Kong from 2009 to 2019—discrepancies of anaphylaxis care between adult and paediatric patients

机译:从2009年到2019年到2019年,2019年的过敏性发病率,成人和儿科患者的过敏性护理

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Anaphylaxis has been increasing in developed countries but there is very little published data on the burden of anaphylaxis and the pattern of adrenaline autoinjector (AAI) prescription from Asia. We aim to determine the incidence rates of anaphylaxis and prescription rates of AAI over the past decade in Hong Kong. Using a centralized electronic database of Hong Kong’s sole public-funded healthcare provider, we obtained and analysed all patients between 2009 and 2019 with physician-reported diagnosis of anaphylaxis. Incidence rates were calculated using population statistics as the denominator. Patients’ prescriptions on discharge were collected to determine the AAI prescription rates. The overall 10-year estimated incidence rate of anaphylaxis was 3.57 per 100,000 person-years. An increasing trend over time across both paediatric and adult populations from 2009 to 2014 was found, which remained stable until 2019. This was more marked among the paediatric population (paediatric vs adult incidence rate ratio in 2019: 3.51 [95% CI 1.12–2.66] vs 1.82 [95% CI 1.05–1.60]). There was an overall increasing rate of AAI prescription for patients admitted for anaphylaxis, but the overall AAI prescription rate was less than 15% and was significantly less likely to be prescribed for the adult compared to paediatric patients (36.5% vs. 89.4%, p??0.001). An increasing trend of anaphylaxis incidence rates over the past decade is evident in Asian populations, with a discrepantly low rate of AAI prescription, particularly in the adult patients.
机译:发达国家在发达国家越来越多地发表了关于过敏反应的负担以及亚洲肾上腺素自身注射器(AAI)处方的标准很少。我们的目标是在过去十年中确定AAI的过敏反应和处方率的发病率。我们使用香港唯一的公共资助医疗保健提供商的集中电子数据库,并分析了2009年至2019年期间的所有患者,与医生报告的过敏反应诊断。使用群体统计数据作为分母计算发病率。收集患者的放电处方以确定AAI处方率。整体10年的过敏反应发病率为每10万人为3.57人。从2009年至2014年跨越儿科和成年人群的时间越来越大,直到2019年仍然保持稳定。这在儿科人口(2019年儿科与成年人发病率比率:3.51 [95%CI 1.12-2.66 ] Vs 1.82 [95%CI 1.05-1.60])。对于过敏反应的患者,AAI处方的总体上升率较高,但总体AAI处方率少于15%,与儿科患者相比,成人规定的可能性明显不太可能(36.5%vs.89.4%,P ?<?0.001)。在过去十年中,在亚洲群体中,过渡期发生的趋势越来越明显,均衡率低的AAI处方率,特别是在成年患者中。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号